# US Blood Plasma Derivatives Market

> US Blood Plasma Derivatives Market Research Report By Type (Albumin, Immunoglobulin, Factor VIII, Factor IX, Hyperimmune Globulin),End-User (Medical Centers, Clinics), By Application (Hemophilia, Immunodeficiency Diseases, Hypogammaglobulinemia, Von Willebrand's Disease), By Region - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.86%
- **2024:** $ 9.09 Billion
- **2025:** $ 9.79 Billion
- **2035:** $ 17.02 Billion
- **Key Players:** Grifols (US), CSL Behring (US), Takeda Pharmaceutical Company Limited (US), Octapharma (US), Kedrion Biopharma (US), Bio Products Laboratory (US), LFB Biomedicaments (US), Hualan Biological Engineering (US)

**Report ID:** MRFR/Pharma/16771-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-plasma-derivatives-market-18299

---

## Market Summary

## US Blood Plasma Derivatives Market Highlighted Trends & Dynamics

The demand for blood plasma derivatives in the United States has been on a steady rise, driven by various factors that reflect the evolving healthcare landscape. One significant contributor to this demand is the increasing prevalence of chronic diseases and medical conditions that necessitate therapeutic interventions. Conditions such as hemophilia, immune deficiencies, and certain neurological disorders require the use of blood plasma derivatives for effective treatment. As the aging population in the U.S. continues to grow, there is a simultaneous increase in the incidence of these health issues, further fueling the demand for blood plasma derivatives. Technological advancements and continuous research efforts also play a crucial role in driving the demand for blood plasma derivatives in the U.S. Ongoing innovation in manufacturing processes, purification techniques, and viral inactivation methods enhances the safety and efficacy of these products, fostering confidence among healthcare professionals and patients. The introduction of new and improved derivatives contributes to the diversification of treatment options, meeting the specific needs of a broader patient population and driving overall market demand. The regulatory landscape in the U.S. is another factor influencing the demand for blood plasma derivatives. Stringent regulations and standards set by the U.S. Food and Drug Administration (FDA) ensure the safety, quality, and efficacy of these products. Compliance with these regulations is paramount for market players, and the rigorous oversight provides assurance to healthcare providers and patients, contributing to sustained demand for blood plasma derivatives. Economic factors also contribute to the demand dynamics of the U.S. [blood plasma derivatives market](../../../reports/blood-plasma-derivatives-market-1325). The country's robust healthcare infrastructure and high healthcare spending capacity enable widespread access to advanced medical treatments, including those involving blood plasma derivatives. The willingness of patients and healthcare professionals to adopt innovative therapies, coupled with a favorable reimbursement environment, further supports the sustained demand for these products. Market competition and the presence of key players in the U.S. blood plasma derivatives market contribute to the demand landscape. The market is characterized by the presence of major pharmaceutical and biotechnology companies, engaging in research, development, and strategic initiatives to capture and expand their market share. Competition fosters innovation, drives product development, and contributes to a dynamic market environment, meeting the diverse demands of the U.S. healthcare system. Geopolitical factors also play a role in shaping the demand for blood plasma derivatives in the U.S. Policies related to trade, international collaborations, and geopolitical stability influence the supply chain and market access. Companies operating in this market need to navigate these factors to ensure a stable supply and meet the growing demand for blood plasma derivatives in the U.S. Moreover, heightened awareness and education about blood plasma derivatives among healthcare professionals and patients contribute to increased demand. Educational programs, advocacy efforts, and awareness campaigns highlight the therapeutic benefits of these derivatives, leading to higher adoption rates and an expanded market. As patients become more informed about available treatments, there is a growing demand for these products to address various medical conditions.

## Market Drivers

### Increasing Prevalence of Chronic Diseases

The US Blood Plasma Derivatives Market is experiencing growth due to the rising prevalence of chronic diseases such as hemophilia, immune deficiencies, and other blood-related disorders. According to the Centers for Disease Control and Prevention, approximately 1 in 1,000 individuals in the US are affected by hemophilia, leading to a heightened demand for plasma-derived therapies. This trend is likely to continue as the population ages and the incidence of chronic conditions increases. The need for immunoglobulins and clotting factors derived from blood plasma is expected to drive market expansion, as healthcare providers seek effective treatments for these conditions. Consequently, the US Blood Plasma Derivatives Market is poised for significant growth, as it addresses the therapeutic needs of a growing patient population.

### Rising Demand for Specialty Plasma Products

The US Blood Plasma Derivatives Market is witnessing a surge in demand for specialty plasma products, such as hyperimmune globulins and specific clotting factors. This trend is driven by the increasing recognition of the unique therapeutic benefits these products offer for rare diseases and specific patient populations. For instance, hyperimmune globulins are utilized in treating conditions like rabies and hepatitis B, which require targeted therapies. The market for these specialty products is projected to expand as healthcare providers seek tailored solutions for their patients. Consequently, the US Blood Plasma Derivatives Market is likely to experience robust growth, as it adapts to the evolving needs of the healthcare landscape.

### Regulatory Support for Plasma-Derived Therapies

The US Blood Plasma Derivatives Market is positively influenced by regulatory support for plasma-derived therapies. The Food and Drug Administration (FDA) has established guidelines that facilitate the approval and commercialization of new plasma products. This regulatory framework not only ensures the safety and efficacy of these therapies but also encourages innovation within the industry. As a result, pharmaceutical companies are more inclined to invest in research and development of novel plasma-derived treatments. The supportive regulatory environment is likely to foster growth in the US Blood Plasma Derivatives Market, as it enables quicker access to essential therapies for patients in need.

### Advancements in Plasma Fractionation Technologies

Technological innovations in plasma fractionation are playing a pivotal role in the US Blood Plasma Derivatives Market. Enhanced methods for separating and purifying plasma components have led to increased yields and improved product quality. For instance, the introduction of automated systems and advanced filtration techniques has streamlined the production process, making it more efficient. As a result, manufacturers can meet the rising demand for plasma-derived products, such as albumin and clotting factors, more effectively. The market is projected to grow as these advancements not only reduce production costs but also enhance the safety and efficacy of the final products. This technological evolution is likely to bolster the US Blood Plasma Derivatives Market, ensuring a steady supply of essential therapies.

### Growing Awareness and Acceptance of Plasma Donation

The US Blood Plasma Derivatives Market is benefiting from an increase in public awareness and acceptance of plasma donation. Campaigns aimed at educating the public about the importance of plasma donation have led to a rise in donor participation. According to the American Red Cross, the number of registered plasma donors has seen a notable increase, which is crucial for maintaining a stable supply of plasma for therapeutic use. This growing acceptance is likely to enhance the availability of raw materials for plasma-derived products, thereby supporting the market's growth. As more individuals recognize the life-saving potential of their contributions, the US Blood Plasma Derivatives Market is expected to thrive, ensuring that patients have access to necessary treatments.

## Future Outlook

The US Blood Plasma Derivatives Market is projected to grow at a 5.86% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulins and advancements in collection technologies.

**New opportunities:**

- Expansion of telehealth services for plasma donation scheduling. Development of specialized plasma-derived therapies for rare diseases. Investment in automated plasma collection centers to enhance efficiency.

By 2035, the market is expected to solidify its position as a leader in biopharmaceutical innovations.

## Segment Insights

### By Type: Immunoglobulin (Largest) vs. Albumin (Fastest-Growing)

In the US blood plasma-derivatives market, the market share is predominantly held by immunoglobulin, with its applications in various therapeutic areas driving significant demand. Albumin follows, gaining traction due to its critical role in treating liver diseases and as a colloidal solution for maintaining plasma volume. Factor VIII and Factor IX, while important, comprise a smaller share of the market due to their specific usage in hemophilia treatments. Hyperimmune globulin, although niche, supports targeted therapies for specific infections and provides substantial contributions to the overall landscape.

Growth trends within this segment are influenced by an increasing prevalence of chronic diseases and a growing aging population requiring plasma-derived therapies. Additionally, ongoing advancements in research and logistics have improved collection and processing efficiencies, fostering market growth. The push for more effective treatments and the expansion of healthcare access are contributing factors to the burgeoning demand, especially for the fastest-growing segment, which is albumin, due to its versatility in treatment protocols.

Immunoglobulin (Dominant) vs. Albumin (Emerging)

Immunoglobulin remains the dominant segment in the US blood plasma-derivatives market, largely due to its essential role in immune deficiencies and inflammatory diseases. Its broad therapeutic applications underpin its market leadership, as it is utilized extensively in both hospital and outpatient settings. In contrast, albumin is emerging rapidly, driven by its increasing use in critical care scenarios, including surgery and trauma. Characterized by its ability to regulate oncotic pressure and maintain blood volume, albumin's versatility makes it attractive to healthcare providers. The growth for albumin is fueled by heightened awareness about its benefits and a shift towards more individualized patient care in critical conditions.

### By Application: Hemophilia (Largest) vs. Immunodeficiency Diseases (Fastest-Growing)

In the US blood plasma-derivatives market, Hemophilia stands out as the largest application segment, reflecting significant patient populations reliant on factor replacement therapies. This segment has established a robust market presence, dominating the landscape due to the increasing diagnosis and treatment options available for hemophilia patients. Conversely, Immunodeficiency Diseases are emerging rapidly, driven by advancements in treatment methodologies and a growing awareness of these conditions among healthcare practitioners.

The growth trends in the application segment are primarily fueled by the rising prevalence of blood-related disorders and continued innovation in plasma-derived therapies. Factors such as increasing healthcare expenditure, supportive regulatory frameworks, and technological advancements are propelling Immunodeficiency Diseases to be recognized as the fastest-growing segment. Furthermore, the enhanced focus on personalized medicine and patient-centric therapies paves the way for accelerated development across the segment.

Hemophilia (Dominant) vs. Von Willebrand's Disease (Emerging)

Hemophilia remains the dominant force within the application segment, characterized by well-established treatment protocols including clotting factor concentrates. This segment's stronghold is attributed to the high incidence rate and the continuing need for effective management strategies in hemophilic patients. In contrast, Von Willebrand's Disease is regarded as an emerging condition gaining attention in the US blood plasma-derivatives market. This condition, often underdiagnosed, is now being recognized more frequently, leading to enhanced product offerings aimed at managing the symptoms. The increasing recognition of von Willebrand's Disease in clinical settings is fostering innovation and expanding treatment options, contributing significantly to its market traction.

### By End-User: Medical Centers (Largest) vs. Clinics (Fastest-Growing)

The market share distribution among the end-user segment of the US blood plasma-derivatives market reveals that Medical Centers hold a significantly larger portion compared to Clinics. Medical Centers are prominent players due to their established infrastructures and extensive patient bases, enabling them to leverage blood plasma derivatives effectively. Meanwhile, Clinics, although comprising a smaller share, demonstrate a rapid growth trajectory, appealing to an increasing population seeking outpatient services and personalized healthcare.

Growth trends indicate that the demand for blood plasma derivatives in Medical Centers will remain stable, driven by their ongoing need for advanced treatment options and emergency care. In contrast, Clinics are witnessing accelerated growth as they adapt to the health care landscape by offering specialized plasma treatments. This shift is supported by an increased emphasis on accessibility and convenience for patients, positioning Clinics as a vital emerging segment in the market.

Medical Centers (Dominant) vs. Clinics (Emerging)

Medical Centers serve as the dominant force within the end-user segment of the US blood plasma-derivatives market, benefiting from comprehensive facilities and a vast range of services. These institutions have the ability to provide advanced treatments and have established relationships with pharmaceutical companies, impacting their operational effectiveness. Conversely, Clinics are classified as an emerging segment, appealing to patients seeking convenient healthcare options. Their growth is propelled by innovations in treatment protocols and a focus on patient-centric care. Clinics are adapting swiftly to industry trends, promoting the use of plasma derivatives for a variety of conditions, thus capturing market interest and paving the way for future expansion.

## Competitive Benchmarking

The [Blood Plasma Derivatives Market](https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325) is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansions. Key players such as Grifols (US), CSL Behring (US), and Takeda Pharmaceutical Company Limited (US) are actively pursuing strategies that enhance their market positioning. Grifols (US) focuses on expanding its product portfolio through research and development, while CSL Behring (US) emphasizes strategic acquisitions to bolster its capabilities in immunoglobulin therapies. Takeda Pharmaceutical Company Limited (US) appears to be leveraging its global footprint to enhance distribution networks, thereby increasing accessibility to its plasma-derived products. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and operational efficiency are paramount.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market structure is moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, yet the influence of major companies remains significant, as they set industry standards and drive technological advancements.
In December 2025, Grifols (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation therapies derived from human plasma. This collaboration is expected to enhance Grifols' R&D capabilities and accelerate the introduction of innovative treatments, thereby reinforcing its competitive edge in the market. The strategic importance of this partnership lies in its potential to expand Grifols' therapeutic offerings and improve patient outcomes, aligning with the growing demand for advanced plasma therapies.
In November 2025, CSL Behring (US) completed the acquisition of a smaller biotech company specializing in rare disease treatments. This acquisition is likely to enhance CSL Behring's product pipeline and strengthen its position in niche markets. The strategic move underscores the company's commitment to expanding its therapeutic range and addressing unmet medical needs, which could lead to increased market share and revenue growth.
In October 2025, Takeda Pharmaceutical Company Limited (US) launched a new plasma-derived product aimed at treating chronic immune disorders. This product introduction is significant as it not only diversifies Takeda's portfolio but also responds to the rising demand for specialized therapies. The launch reflects Takeda's focus on innovation and its ability to adapt to evolving market needs, positioning the company favorably against competitors.
As of January 2026, current trends in the Blood Plasma Derivatives Market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in operations. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize R&D and operational excellence will be better positioned to thrive in an increasingly complex market.

## Report Scope

| MARKET SIZE 2024 | 9.09(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.79(USD Billion) |
| MARKET SIZE 2035 | 17.02(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.86% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Grifols (US), CSL Behring (US), Takeda Pharmaceutical Company Limited (US), Octapharma (US), Kedrion Biopharma (US), Bio Products Laboratory (US), LFB Biomedicaments (US), Hualan Biological Engineering (US) |
| Segments Covered | Application, Product Type, End User |
| Key Market Opportunities | Advancements in therapeutic applications drive growth in the US Blood Plasma Derivatives Market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive growth in the US Blood Plasma Derivatives Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the projected market valuation for the US blood plasma-derivatives market in 2035?**
A: The projected market valuation for the US blood plasma-derivatives market in 2035 is $19.2 Billion.

**Q: What was the market valuation of the US blood plasma-derivatives market in 2024?**
A: The market valuation of the US blood plasma-derivatives market in 2024 was $9.5 Billion.

**Q: What is the expected CAGR for the US blood plasma-derivatives market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US blood plasma-derivatives market during the forecast period 2025 - 2035 is 6.61%.

**Q: Which segment is projected to have the highest valuation in the US blood plasma-derivatives market by 2035?**
A: By 2035, the Immunoglobulin segment is projected to have the highest valuation, reaching $7.0 Billion.

**Q: What are the key applications driving the US blood plasma-derivatives market?**
A: Key applications driving the market include Hemophilia, Immunodeficiency Diseases, and Von Willebrand's Disease.

**Q: Which end-user segment is expected to grow significantly in the US blood plasma-derivatives market?**
A: The Medical Centers end-user segment is expected to grow significantly, with a projected valuation of $11.5 Billion by 2035.

**Q: Who are the leading players in the US blood plasma-derivatives market?**
A: Leading players in the market include Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma.

**Q: What was the valuation of the Factor VIII segment in 2024?**
A: The valuation of the Factor VIII segment in 2024 was $1.2 Billion.

**Q: How does the projected growth of the Immunodeficiency Diseases application compare to other applications?**
A: The Immunodeficiency Diseases application is projected to grow to $5.0 Billion, indicating robust growth compared to other applications.

**Q: What is the expected valuation for the Clinics end-user segment by 2035?**
A: The expected valuation for the Clinics end-user segment by 2035 is $7.7 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-plasma-derivatives-market-18299*